MET and hepatocellular carcinoma: In other settings, such as hepatocellular carcinoma cells, deguelin attenuates hepatocyte growth factor (HGF)-mediated HGF receptor (a.k.a. c-Met) activation, leading to vascular endothelial growth factor (VEGF) suppression, thereby suppressing angiogenesis and reducing pro-angiogenic factors in these cells [33].